Advertisement
Screener

Immuneering Corporation (IMRX) Material Contracts

Immuneering Corporation Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-08-05: Form 10-Q; Exhibit 10.2; Description Immuneering Corporation 2025 Employment Inducement Award Plan and forms of award agreements thereunder, as amended, effective June 11, 2026.
  • 2026-08-05: Form 10-Q; Exhibit 10.1; Description Employment Agreement, dated June 10, 2026, by and between Andrew Gengos and Immuneering Corporation.
  • 2026-03-06: Form 10-K; Exhibit 10.15; Description Immuneering Corporation Non-Employee Director Compensation Program, as amended, effective January 1, 2026.
  • 2025-11-12: Form 10-Q; Exhibit 10.1; Description Immuneering Corporation Non-Employee Director Compensation Program, as amended, effective August 12, 2025.
FiledFormExhibitDescription
2026-08-0510-Q10.2Immuneering Corporation 2025 Employment Inducement Award Plan and forms of award agreements thereunder, as amended, effective June 11, 2026
2026-08-0510-Q10.1Employment Agreement, dated June 10, 2026, by and between Andrew Gengos and Immuneering Corporation
2026-03-0610-K10.15Immuneering Corporation Non-Employee Director Compensation Program, as amended, effective January 1, 2026
2025-11-1210-Q10.1Immuneering Corporation Non-Employee Director Compensation Program, as amended, effective August 12, 2025
2025-09-248-K10.1Securities Purchase Agreement, dated as of September 24, 2025, by and between Immuneering Corporation and Aventis Inc.
2025-08-258-K10.2Form of Registration Rights Agreement, dated as of August 21, 2025, by and among Immuneering Corporation and the Investors party thereto.
2025-08-258-K10.1Form of Securities Purchase Agreement, dated as of August 21, 2025, by and among Immuneering Corporation and the Investors party thereto.
2025-03-2010-K10.14Immuneering Corporation 2025 Employment Inducement Award Plan and forms of award agreements thereunder
2024-08-0610-Q10.1Immuneering Corporation Non-Employee Director Compensation Program, as amended
2024-03-0110-K10.15Immuneering Corporation Non-Employee Director Compensation Program, as amended, effective January 1, 2024
2024-03-0110-K10.8Employment Agreement, dated March 24, 2023, by and between Harold E. Brakewood and Immuneering Corporation
2024-03-0110-K10.6Letter Agreement, dated June 14, 2023, by and between Mallory Morales and Immuneering Corporation
2024-03-0110-K10.4Employment Agreement, dated July 23, 2021, by and between Mallory Morales and Immuneering Corporation
2023-11-0910-Q10.2Separation Agreement and Release, by and between Scott Barrett and Immuneering Corporation, dated November 8, 2023
2023-11-0910-Q10.1Immuneering Corporation Non-Employee Director Compensation Program, as amended, effective October 16, 2023
2023-08-0310-Q10.1Immuneering Corporation Non-Employee Director Compensation Program, as amended, effective June 13, 2023
2022-07-258-K10.1Letter Agreement, by and between Immuneering Corporation and Mallory Morales, dated as of July 25, 2022
2021-12-228-K10.1Lease Agreement, by and between BioArkive, Inc, and Thornmint 13, LLC, dated as of July 22, 2021

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quantum Cyber N.V. (QUCY)$0.113B
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
GENELUX Corp (GNLX)United States$0.110B-3.83
Equillium, Inc. (EQ)United States$0.109B-11.27
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80